• News
  • SAN DIEGO
  • BioTech

Zogenix hits all-time low after panel opposition

Shares of San Diego-based Zogenix tumbled to an all-time low Monday after U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone.

On Friday the Food and Drug Administration's panel of pain specialists voted 11-2 with one abstention against Zohydro for moderate to severe chronic pain. The drug was developed as a long-acting pain reliever by Zogenix Inc. (Nasdaq: ZGNX).

The panelists acknowledged that the pill would likely reduce pain, but worried it would exacerbate the U.S. epidemic of prescription painkiller abuse.

The FDA is not required to follow the group's recommendation, though it often does so. It is scheduled to make its decision on the drug by March 1.

Oppenheimer's Christopher Holterhoff downgraded Zogenix to “perform” from “outperform” and removed its $3 price target.

The analyst said in a client note that he does not anticipate Zogenix will receive FDA approval. He anticipates that the company will continue to work with the FDA on matters of concern in an effort to potentially receive approval for Zohydro in the future.

Zogenix Inc.'s stock fell $1.25, or 50.1 percent, to close Monday at $1.16, its lowest level since the shares went public in November 2010.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Zogenix Inc.

Company Website

12400 High Bluff Dr. Ste., 650
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ZGNX
13.53
  -0.06  
- 0.44%
335,635,000
21.65
8.64

Zogenix Inc. Executive(s):

Roger Hawley

  • Chief Executive Officer

Stephen Farr

  • President

Ann Rhoads

  • Chief Financial Officer
Subscribe Today!